시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 재발 두경부 편평상피암 시장 보고서(2025년)
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Market Report 2025
상품코드 : 1720877
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,319,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,134,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,949,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

재발 두경부 편평상피암 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 병존질환의 유병률 증가, 의료보험 적용 확대가 견인할 것으로 보입니다.

맞춤형 의료의 확대가 재발 두경부 편평상피암 시장의 성장을 견인할 것으로 예측됩니다. 루스케어에 대한 결정을 커스터마이징하는 의료 접근법입니다. 맞춤형 의료의 대두는 유전체 연구의 진보, 진단 기술의 향상, 맞춤형 치료에 대한 수요 증가, 정밀의료에 대한 투자 증가에 의해 하여 촉진되고 보다 효과적이고 맞춤 치료가 가능해지고 있습니다. 재발 두경부 편평상피암 치료에서 개인 맞춤형 의학은 유전자 프로파일링과 표적 치료법을 사용하여 각 환자의 종양 고유한 분자특성에 특이적으로 대처하는 치료계획을 세울 수 있도록 합니다. 개인 맞춤 의학 연합(Personalized Medicine Coalition)은 미국 식품의약국이 희소질환 환자를 위해 16개의 새로운 맞춤형 치료를 승인했다고 보고했으며, 이는 2022년 6개 에서 증가한 수치입니다.

재발 두경부 편평상피암시장의 주요 기업은 치료효과를 높이고 환자의 결과를 개선하며, 이 공격적인 암과 관련된 암메트 메디컬 니즈에 대응하기 위해 혁신적인 면역암 치료제의 개발에 주력하고 있습니다. 면역 세포의 활동을 촉진하거나 면역세포가 종양을 표적으로 하는 것을 방해하는 면역체크포인트를 차단함으로써 면역반응을 자극 또는 강화함으로써 신체의 면역계를 이용하여 암세포를 검출 및 공격합니다. Aveta Biomics Inc.는 미국 식품 의약품국(FDA)으로부터, 두경부암의 치료제로서 강황 유래의 임상용 면역종양약 APG-157의 패스트 트랙 지정을 받았습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Recurrent head and neck cancer squamous cell carcinoma refers to the reappearance of squamous cell carcinoma in the head and neck region after initial treatment, originating from the mucosal epithelium. It is associated with a poor prognosis, with median survival rates ranging from 6 to 15 months, highlighting the need for innovative treatment strategies and multimodal management approaches.

The primary treatment options for recurrent head and neck cancer squamous cell carcinoma include chemotherapy, immunotherapy, targeted drug therapy, and others. Chemotherapy involves the use of potent drugs to destroy or slow the growth of cancer cells. Treatment is administered through various routes, including oral and parenteral methods, and is utilized by multiple end users such as hospitals, clinics, diagnostic centers, and research laboratories.

The recurrent head and neck cancer squamous cell carcinoma market research report is one of a series of new reports from The Business Research Company that provides recurrent head and neck cancer squamous cell carcinoma market statistics, including the recurrent head and neck cancer squamous cell carcinoma industry's global market size, regional shares, competitors with a recurrent head and neck cancer squamous cell carcinoma market share, detailed recurrent head and neck cancer squamous cell carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the recurrent head and neck cancer squamous cell carcinoma industry. This recurrent head and neck cancer squamous cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The recurrent head and neck cancer squamous cell carcinoma market size has grown strongly in recent years. It will grow from $3.10 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period was driven by the increasing prevalence of head and neck cancers worldwide, greater awareness of early detection and treatment options, a growing geriatric population, the expanding availability of combination therapies, and a rise in healthcare expenditure.

The recurrent head and neck cancer squamous cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $4.36 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period is expected to be driven by the rising demand for biologics, increased use of telemedicine, a growing focus on supportive care, the increasing prevalence of comorbidities, and expanding health insurance coverage. Key trends include advancements in robotic-assisted surgical techniques, innovations in radiation therapy technologies, progress in 3D printing applications, the development of bispecific antibodies, and the integration of artificial intelligence in diagnostic imaging.

The expansion of personalized medicine is expected to drive the growth of the recurrent head and neck cancer squamous cell carcinoma market. Personalized medicine is a medical approach that customizes treatment and healthcare decisions based on individual patient characteristics, such as genetic profile, environment, and lifestyle. The rise of personalized medicine is fueled by advancements in genomic research, improved diagnostic technologies, increasing demand for tailored treatments, and growing investments in precision healthcare, allowing for more effective and individualized therapies. In the treatment of recurrent head and neck cancer squamous cell carcinoma, personalized medicine enables the use of genetic profiling and targeted therapies to develop treatment plans that specifically address the unique molecular characteristics of each patient's tumor. For example, in February 2024, the Personalized Medicine Coalition, a US-based organization advocating for the adoption of personalized medicine, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the growth of personalized medicine is contributing to the expansion of the recurrent head and neck cancer squamous cell carcinoma market.

Leading companies in the recurrent head and neck cancer squamous cell carcinoma market are focusing on developing innovative immuno-oncology drugs to enhance treatment efficacy, improve patient outcomes, and address the unmet medical needs associated with this aggressive form of cancer. Immuno-oncology drugs harness the body's immune system to detect and attack cancer cells by stimulating or enhancing immune responses, either by boosting immune cell activity or by blocking immune checkpoints that prevent immune cells from targeting tumors. For instance, in August 2024, Aveta Biomics Inc., a US-based pharmaceutical company, received fast-track designation from the U.S. Food and Drug Administration (FDA) for APG-157, an investigational immuno-oncology agent derived from turmeric for the treatment of head and neck cancer. Its dual mechanism selectively targets cancer cells while reshaping the immune environment, potentially offering a less invasive alternative to surgery and intensive therapies.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition strengthens AstraZeneca's oncology portfolio by incorporating advanced radiopharmaceuticals such as FPI-2265, enhancing research and development as well as manufacturing capabilities. The move accelerates the transition to targeted cancer therapies while expanding AstraZeneca's presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based company specializing in next-generation radiopharmaceuticals designed as precision medicines for oncology.

Major players in the recurrent head and neck cancer squamous cell carcinoma market are Roche Holding AG, Merck KGaA, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Incyte Corporation, BeiGene Ltd., BioNTech SE, Exelixis Inc., CytomX Therapeutics Inc., CureVac AG, Zymeworks Inc., MacroGenics Inc., Kura Oncology Inc., Genexine Inc.

North America was the largest region in the recurrent head and neck cancer squamous cell carcinoma market in 2024. The regions covered in recurrent head and neck cancer squamous cell carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the recurrent head and neck cancer squamous cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The recurrent head and neck cancer squamous cell carcinoma market includes revenues earned by entities by providing services such as diagnostic services, surgical services, radiation therapy, and multidisciplinary care and related products such as linear accelerators, positron emission tomography (PET) scanners, and magnetic resonance imaging (MRI) machines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on recurrent head and neck cancer squamous cell carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for recurrent head and neck cancer squamous cell carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The recurrent head and neck cancer squamous cell carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Characteristics

3. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Trends And Strategies

4. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Growth Analysis And Strategic Analysis Framework

6. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Segmentation

7. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Regional And Country Analysis

8. Asia-Pacific Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

9. China Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

10. India Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

11. Japan Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

12. Australia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

13. Indonesia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

14. South Korea Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

15. Western Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

16. UK Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

17. Germany Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

18. France Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

19. Italy Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

20. Spain Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

21. Eastern Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

22. Russia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

23. North America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

24. USA Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

25. Canada Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

26. South America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

27. Brazil Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

28. Middle East Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

29. Africa Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

30. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Competitive Landscape And Company Profiles

31. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Other Major And Innovative Companies

32. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

34. Recent Developments In The Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

35. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기